Relapse- and Immunosuppression-Free Survival after Hematopoietic Stem Cell Transplantation: How Can We Assess Treatment Success for Complex Time-to-Event Endpoints?

Bluhmki, Tobias; Schmoor, Claudia; Finke, Jürgen; Schumacher, Martin; Socié, Gérard; Beyersmann, Jan

Bluhmki, Tobias; Schmoor, Claudia; Finke, Jürgen; Schumacher, Martin; Socié, Gérard; Beyersmann, Jan.

Afiliação

Bluhmki T; Institute of Statistics, Ulm University, Ulm, Germany. Electronic address: tobias.bluhmki@alumni.uni-ulm.de.
Schmoor C; Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Finke J; Department of Hematology, Oncology, and Stem-Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Schumacher M; Institute for Medical Biometry and Medical Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Socié G; Université de Paris, INSERM U976 and Hématologie-Transplantation, Hôpital St. Louis, Paris, France.
Beyersmann J; Institute of Statistics, Ulm University, Ulm, Germany.

Biol Blood Marrow Transplant ; 26(5): 992-997, 2020 05.

Article em En | MEDLINE | ID: mdl-31927103

Assuntos

Doença Enxerto-Hospedeiro; Transplante de Células-Tronco Hematopoéticas; Soro Antilinfocitário; Intervalo Livre de Doença; Doença Enxerto-Hospedeiro/prevenção & controle; Humanos; Recidiva; Condicionamento Pré-Transplante; Resultado do Tratamento

Palavras-chave

Complex time-to-event endpoints; Multistate model; Relapse- and immunosuppression-free survival; Resampling; Stem cell transplantation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google